Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | KIF11 | P52732 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5352815 | 0.88 | KIF11 (0.65) | POLBKIF11ALDH1A1PKM | |
| SCHEMBL5352781 | 0.87 | KIF11 (0.77) | KIF11ALDH1A1PKMSMN1; SMN2 | |
| SCHEMBL10113145 | 0.85 | HSD17B10 (0.67) | POLBKIF11PKM | |
| SCHEMBL5343438 | 0.84 | POLB (0.63) | POLBKIF11PKMPDE1CSMN1; SMN2 | |
| SCHEMBL5337520 | 0.83 | MAPT (0.66) | POLBKIF11PKM | |
| SCHEMBL10113135 | 0.79 | GAA (0.64) | POLBKIF11ALDH1A1PKM | |
| SCHEMBL10113437 | 0.79 | ADORA2B (0.61) | KIF11ALDH1A1PKM | |
| SCHEMBL16457636 | 0.79 | TSHR (0.70) | TSHRPKM | |
| SCHEMBL7688891 | 0.76 | ALDH1A1 (0.61) | POLBALDH1A1 | |
| SCHEMBL5340534 | 0.75 | KIF11 (0.80) | POLBTSHRKIF11ALDH1A1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120100609-A1 | N-LINKED GLYCAN BIOSYNTHESIS MODULATORS | BIOMARIN PHARMACEUTICAL INC. | 2012-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120100609-A1 | N-LINKED GLYCAN BIOSYNTHESIS MODULATORS | ENGASE, GALNT1, GALNT13 | POLB 2362/4885TSHR 2802/4885KIF11 3347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.